New hope for children with returning leukemia: blinatumomab trial launches in china

NCT ID NCT06054113

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times

Summary

This study tests a drug called blinatumomab in Chinese children (ages 1 month to 18 years) whose B-cell acute lymphoblastic leukemia has come back or not responded to standard treatment. The main goal is to see how many children achieve complete remission. The study also monitors side effects and how the drug moves through the body. It is a phase 2, open-label trial with 18 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Hospital of Soochow University

    Suzhou, Jiangsu, 215002, China

  • Childrens Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, 400015, China

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, 300020, China

  • Shanghai Children's Medical Center

    Shanghai, Shanghai Municipality, 200127, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, 230601, China

  • Wuhan Childrens Hospital

    Wuhan, Hubei, 430015, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, 510280, China

Conditions

Explore the condition pages connected to this study.